The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.
The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.
Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.
Tech Trader Only
(Technical Analysis + Trades by Tech Trader)
Grok's Analysis
| 2026-04-10 | HOLD LONG |
| 2026-04-09 | HOLD LONG |
|
Summary: ...
|
|
| 2026-04-08 | HOLD LONG |
|
Summary: ...
|
|
| 2026-04-07 | BUY |
|
Summary: I'm going long ABBV around 205.73 on 4/7/2026 as the daily chart shows a pullback to support near March lows with oversold conditions, while strong buy consensus, $250 average targets, and 2026 EPS growth from Skyrizi/Rinvoq make it undervalued with solid rebound potential. ...
|
|
| 2026-04-06 | CASH |
|
Summary: Staying in CASH for ABBV at 206.2 on 4/6/2026 after selling at 208.84 on 4/2 because daily chart shows lower highs since March 237 peak, recent breakdown below 210, and repeated negative earnings surprises like -19.1% last quarter with weak price reaction. ...
|
|
| 2026-04-02 | SOLD |
|
Summary: We're moving to CASH on the existing long from $207.18, as ABBV closed sharply lower at $208.32 below its EMA and SMA with RSI dropping to 39.5 after a big red candle. ...
|
|
| 2026-04-01 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-31 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-30 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-27 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-26 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-25 | BUY |
|
Summary: We stayed in cash due to lack of conviction after the breakdown but today's bounce off support with a 209.68 high, higher close and fresh positive partnership news changes the picture so we're going long now....
|
|
| 2026-03-24 | CASH |
|
Summary: ...
|
|
| 2026-03-23 | CASH |
|
Summary: ...
|
|
| 2026-03-20 | COVERED |
|
Summary: We went short on the breakdown amid competitive pressure but after a solid 4-point gain as it tests February lows around 204 with no further acceleration or major new negatives we're covering to cash....
|
|
| 2026-03-19 | HOLD SHORT |
|
Summary: Holding our short from yesterday as the stock continues showing weak price action near the lows with no convincing rebound after the breakdown....
|
|
| 2026-03-18 | SHORT |
|
Summary: We stayed in cash due to the short-term downtrend and weak momentum, but today's sharp breakdown below 220 to 207.93 on higher volume changes that so we're now short....
|
|
| 2026-03-17 | CASH |
|
Summary: Still staying in cash because today's session continued the weak, low-volume price action with no meaningful break from the recent short-term downtrend off the March highs....
|
|
| 2026-03-16 | SOLD |
|
Summary: Recent daily price action shows a clear short-term downtrend from the 236 high in early March down to 219.68, with only a weak rebound on low volume, so we're exiting the flat long to protect capital. ...
|
|
| 2026-03-13 | HOLD LONG |
|
Summary: Hold long as price holds above 220 support amid positive Phase 1 results for ABBV-295 obesity analog, strong $67B 2026 revenue guidance from Rinvoq/Skyrizi growth, and analyst buy ratings with $251 target outweighing recent pullback to 222 and bearish MACD crossover....
|
|
| 2026-03-12 | HOLD LONG |
|
Summary: Hold long as uptrend holds above 220 support amid bullish 2026 forecasts, strong drug sales growth, and obesity deal rumors outweighing short-term MACD bearish signals and minor pullback....
|
|
| 2026-03-11 | HOLD LONG |
|
Summary: Maintain long position as uptrend persists above key supports with positive Phase 1 results for ABBV-295 signaling strong pipeline momentum, outweighing short-term MACD bearish crossover....
|
|
| 2026-03-10 | HOLD LONG |
|
Summary: Maintain long position as uptrend persists above key SMA support despite short-term MACD bearish crossover and minor pullback, bolstered by recent positive Phase 1/3 trial results and analyst upgrade signaling strong pipeline momentum....
|
|
| 2026-03-09 | HOLD LONG |
|
Summary: Maintain long as uptrend holds with price above SMA despite minor pullback, positive MACD, and bullish 2026 guidance forecasting 9.5% sales growth amid strong pipeline....
|
|
| 2026-03-06 | HOLD LONG |
|
Summary: Continue long as uptrend persists with price above key EMAs, positive MACD, and bullish SKYRIZI Phase 3 results supporting momentum despite minor pullback....
|
|
| 2026-03-05 | HOLD LONG |
|
Summary: Hold long amid uptrend continuation with price above EMAs, bullish MACD, high STO, and positive SKYRIZI Phase 3 results plus oncology expansions countering today's dip potentially from notes offering digestion....
|
|
| 2026-03-04 | HOLD LONG |
|
Summary: Hold long as price surges to $236.08 breaking resistance with bullish MACD, high STO, RSI 62, and positive Crohn's/SKYRIZI trial results plus growth forecasts outweighing any minor concerns....
|
|
| 2026-03-03 | HOLD LONG |
|
Summary: Hold long as price breaks resistance at $234.68 with bullish MACD crossover, high STO momentum, RSI 61 indicating room to run, and positive news on drug trials, FDA approvals, and expansions outweighing minor insider sales....
|
|
| 2026-03-02 | HOLD LONG |
|
Summary: Hold long as price breaks resistance with bullish MACD crossover, STO momentum, RSI at 60, and positive news on dividends, drug trials, and analyst buys outweigh any minor risks....
|
|
| 2026-02-27 | HOLD LONG |
|
Summary: Hold long as price rebounded strongly above EMAs post-earnings dip, with bullish MACD crossover, positive STO momentum, and no major bearish catalysts amid stable pipeline outlook....
|
|
| 2026-02-26 | HOLD LONG |
|
Summary: Hold long as upbeat 2026 guidance, recent analyst upgrade to moderate buy, and price holding above key EMAs with positive MACD support continued uptrend amid positive pipeline momentum....
|
|
| 2026-02-25 | HOLD LONG |
|
Summary: Hold long as positive analyst upgrades, manufacturing expansions, and upbeat 2026 guidance support continued uptrend with price above key EMAs and positive MACD....
|
|
| 2026-02-24 | HOLD LONG |
|
Summary: Continue long on bullish 2026 guidance with 9.5% revenue growth, manufacturing expansion investments, and Piper Sandler PT raise to $299 amid positive MACD and price above EMAs....
|
|
| 2026-02-23 | HOLD LONG |
|
Summary: $380M US manuf expansion +2% rip to $229.50; 2026 guide beats + $252 avg PT fuel rebound—trail higher....
|
|
| 2026-02-20 | HOLD LONG |
|
Summary: Hold long as ABBV sustains uptrend rebound post-earnings with bullish guidance exceeding expectations and social sentiment eyeing $245-250+ targets, outweighing insider sales and minor pullbacks....
|
|
| 2026-02-19 | HOLD LONG |
|
Summary: Hold long as ABBV maintains uptrend resilience post-earnings rebound, supported by bullish social sentiment targeting $245-250+ breakouts, outweighing today's pullback amid neutral RSI and positive MACD....
|
|
| 2026-02-18 | HOLD LONG |
|
Summary: Hold long position as ABBV rebounds post-earnings with strong 2026 guidance from Skyrizi/Rinvoq driving growth to $67B revenue, outweighing today's pullback amid bullish technicals and sentiment....
|
|
| 2026-02-17 | HOLD LONG |
|
Summary: $232+ hold post-earnings rebound; Strong Buy techs (RSI/MAs bullish) + $251 avg PT on 2026 EPS crush outweigh Rinvoq noise—trail higher....
|
|
| 2026-02-13 | HOLD LONG |
|
Summary: Ripping +3% to $234 on volume post-earnings recovery; Strong Buy techs (RSI 76, all MAs buy) + $251 avg PT fuel momentum—trail higher.[[1]](https://www.gurufocus.com/news/8615969/abbvie-inc-abbv-shares-up-3-on-feb-13)[[2]](https://www.investing.com/equities/abbvie-inc-technical)[[3]](https://www.marketbeat.com/stocks/NYSE/ABBV/forecast)...
|
|
| 2026-02-12 | HOLD LONG |
|
Summary: Rebound to ~$221 holds above entry; Q4 beat/raised 2026 EPS $14.37-14.57 + $251 avg PT outweigh Rinvoq miss—trail higher.[[1]](https://news.abbvie.com/2026-02-04-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2025-Financial-Results)[[2]](https://www.marketbeat.com/stocks/NYSE/ABBV/forecast)...
|
|
| 2026-02-11 | HOLD LONG |
|
Summary: Rebound to $222 holds above entry; earnings beat/guidance raise + Moderate Buy consensus PT $251 outweigh post-report dip—trail higher....
|
|
| 2026-02-10 | HOLD LONG |
|
Summary: Hold long on ABBV as it stabilizes post-earnings dip with technical recovery above key EMAs/SMAs, improving MACD crossover, neutral RSI, and no immediate bearish catalysts outweighing prior positives like raised guidance....
|
|
| 2026-02-09 | HOLD LONG |
|
Summary: Hold long on ABBV as it rebounds from earnings dip with raised 2026 EPS guidance to $14.37-14.57 beating estimates, positive analyst views, and technical recovery above EMA....
|
|
| 2026-02-06 | HOLD LONG |
|
Summary: Hold long on ABBV rebound from earnings dip, supported by raised 2026 EPS guidance beating estimates and Morgan Stanley PT hike to $270 signaling strong growth outlook....
|
|
| 2026-02-05 | HOLD LONG |
|
Summary: Hold long as strong 2026 EPS guidance of $14.37-14.57 beats estimates despite Rinvoq sales miss and competition concerns, with post-earnings dip appearing as overreaction buy signal amid solid Skyrizi/Humira beats and technical rebound potential from $218.7....
|
|
| 2026-01-30 | HOLD LONG |
|
Summary: Holds ~$221 (+0.1% from $220.75 entry); RSI 61 buy/MACD bullish + consensus $245 PT pre-Feb4 earnings—trail higher....
|
|
| 2026-01-27 | HOLD LONG |
|
Summary: $220.77 close holds entry flat; mixed techs (RSI 61 buy/bull flag) + consensus $245 PT (11% upside) pre-earnings favor continuation—trail stops....
|
|
| 2026-01-26 | HOLD LONG |
|
Summary: Consolidating ~$219.50 pre-earnings; Berenberg $275 Buy PT + RSI buy signal (58.8) favor hold despite -4.7% monthly dip—trail stops.[[1]](https://www.investing.com/equities/abbvie-inc-technical)[[2]](https://x.com/i/status/2013656732799504899)[[3]](https://www.zacks.com/stock/news/2822550/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it)...
|
|
| 2026-01-23 | HOLD LONG |
|
Summary: $229 pre-earnings coil; Q4 immunology beats + HSBC/MS PTs $265-269 build steam—trail breakeven+....
|
|
| 2026-01-22 | HOLD LONG |
|
Summary: $228 grind firms pre-earnings; Skyrizi/Rinvoq ramp + analyst PT firepower outweigh vol—trail higher....
|
|
| 2026-01-21 | HOLD LONG |
|
Summary: $227 pre-earnings hold above supports; immunology beats preview + RemeGen collab drive conviction—trail breakeven+....
|
|
| 2026-01-20 | HOLD LONG |
|
Summary: $226 coil tightens above entry; Q4 immunology strength + UBS $240 PT sustain pre-earnings grind—trail higher....
|
|
| 2026-01-16 | HOLD LONG |
|
Summary: $225 grind holds gains; immunology Q4 beats preview + RemeGen oncology collab sustain momentum—trail breakeven+....
|
|
| 2026-01-15 | HOLD LONG |
|
Summary: Q4 preview bullish Skyrizi/Rinvoq beats + TrumpRx pricing relief hold $224.50 gains; uptrend resumes—trail higher....
|
|
| 2026-01-14 | HOLD LONG |
|
Summary: Premarket +1.3% to $223.70 on TrumpRx deal confirmation; oncology/remediation catalysts + UBS $240 PT fuel rebound—trail stops....
|
|
| 2026-01-13 | BUY |
|
Summary: TrumpRx pricing deal + $100B US invest/RemeGen pact offset charge fears, stock flat after-hours stabilizing—re-enter long as new positives flip prior denial/slips rationale....
|
|
| 2026-01-12 | CASH |
|
Summary: Slips persist post-$1.3B R&D charge and RevMed deal denial; pre-earnings vol high with slashed EPS guides—sideline....
|
|
| 2026-01-09 | SOLD |
|
Summary: Recent acquisition denial + slashed EPS guidance on $1.3B R&D charge triggered pullback to $220s; exit long to lock small gain/loss protection pre-earnings volatility....
|
|
| 2026-01-08 | HOLD LONG |
|
Summary: $233 volume push eyes $235; Q4 beats preview + HSBC/MS PTs $265-269 drive pharma momentum—trail stops....
|
|
| 2026-01-07 | HOLD LONG |
|
Summary: $232 grind holds breakout; earnings hype + oncology catalysts build steam—trail to lock gains....
|
|
| 2026-01-06 | HOLD LONG |
|
Summary: $231 consolidation eyes $235; Jan30 earnings tailwinds + HSBC/MS PTs $265-269 anchor pharma grind—trail higher....
|
|
| 2026-01-05 | HOLD LONG |
|
Summary: Steady ~$231 open; Q4 earnings preview buzz + oncology pipeline hype sustain uptrend—trail stops....
|
|
| 2026-01-02 | HOLD LONG |
|
Summary: New Year hold ~$230 resilient; Jan30 earnings hype + HSBC/MS PTs $265-269 propel pharma strength—trail higher....
|
|
| 2025-12-31 | HOLD LONG |
|
Summary: 2025 capper ~$230 on volume; MS/HSBC PTs $265-269 + dividend allure draw year-end buys—uptrend rolls into 2026....
|
|
| 2025-12-30 | HOLD LONG |
|
Summary: Year-end push to $229; Evercore/HSBC PT hikes + oncology data fuel Santa rally extension—trail higher....
|
|
| 2025-12-29 | HOLD LONG |
|
Summary: Post-holiday grind to $228; HSBC/MS PTs $265-269 + dividend yield anchor pharma rotation—trail breakeven+....
|
|
| 2025-12-26 | HOLD LONG |
|
Summary: Holding long ABBV as price at $229.65 stays above key rising support trendline around $224-226 with positive MACD crossover, neutral RSI at 55, and stable pharma fundamentals without major negative news or imminent catalysts....
|
|
| 2025-12-24 | HOLD LONG |
|
Summary: Holding long ABBV as price at $230.13 remains above key rising support trendline around $224-226 with no breakdown, positive MACD crossover emerging, neutral RSI at 56, and stable pharma fundamentals amid lack of negative news....
|
|
| 2025-12-23 | HOLD LONG |
|
Summary: Holding long ABBV as price remains above rising support trendline around $223-226 with no breakdown, neutral RSI and improving MACD crossover, supported by stable pharma sector and lack of negative catalysts despite minor pullback to $228.46....
|
|
| 2025-12-22 | HOLD LONG |
|
Summary: Holding long ABBV as price remains above rising support trendline around $223 with no breakdown, despite minor pullback, supported by positive pharma sector momentum and lack of negative catalysts....
|
|
| 2025-12-19 | HOLD LONG |
|
Summary: Holding long ABBV as price remains above rising support trendline around $223 with no breakdown, despite minor pullback, supported by positive pharma sector momentum and lack of negative catalysts....
|
|
| 2025-12-18 | HOLD LONG |
|
Summary: Holding long ABBV as price holds above key rising support trendline near $223 despite recent pullback, with no breakdown and positive momentum potential from pharma sector strength and upcoming catalysts....
|
|
| 2025-12-17 | HOLD LONG |
|
Summary: Holding long ABBV as price remains above key rising support trendline around $222 with no breakdown, supported by positive momentum from recent bounce and strong fundamentals in immunology drugs despite short-term pullback....
|
|
| 2025-12-16 | HOLD LONG |
|
Summary: Holding long ABBV as price holds above rising support trendline at $221 without breakdown, with positive momentum potential from recent bounce and strong immunology pipeline outweighing short-term weakness....
|
|
| 2025-12-15 | HOLD LONG |
|
Summary: Holding long ABBV as price bounces near rising support trendline at $221 with no breakdown, positive momentum from recent recovery post-earnings, and strong fundamentals in immunology pipeline outweighing short-term pullback....
|
|
| 2025-12-11 | HOLD LONG |
|
Summary: Holding long ABBV position as price remains above key rising support trendline around 221 with no strong reversal signals, positive pharma fundamentals including strong pipeline for Skyrizi and Rinvoq, and potential for recovery in broader market uptrend despite recent pullback....
|
|
| 2025-12-10 | HOLD LONG |
|
Summary: Holding long ABBV as it remains above key rising support levels around 220-223 with no strong reversal signals, positive pharma fundamentals, and broader uptrend intact despite recent pullback....
|
|
| 2025-12-09 | HOLD LONG |
|
Summary: Holding long ABBV as it remains above key rising support levels around $220-223 with no strong reversal signals, positive pharma fundamentals, and broader uptrend intact despite recent pullback....
|
|
| 2025-12-08 | HOLD LONG |
|
Summary: Holding long ABBV as it remains in a broader uptrend with price near rising support around $220-223, positive fundamentals in pharma pipeline, and no imminent catalysts or reversal signals despite short-term pullback....
|
|
| 2025-12-05 | HOLD LONG |
|
Summary: Holding long ABBV as it bounces from rising support near $225 with positive MACD and neutral RSI in broader uptrend, no reversal signals or near-term catalysts, backed by strong fundamentals in immunology and neuroscience pipelines....
|
|
| 2025-12-04 | HOLD LONG |
|
Summary: Holding long ABBV as it consolidates near rising support around $224-227 in broader uptrend, with neutral RSI and no immediate reversal signals or catalysts, supported by strong pharma fundamentals like immunology portfolio growth....
|
|
| 2025-12-03 | HOLD LONG |
|
Summary: Holding long ABBV as it rebounds from support near $224 in ongoing uptrend, with positive momentum, strong fundamentals like robust drug pipeline and dividend yield, and no near-term catalysts or reversal signals....
|
|
| 2025-12-01 | HOLD LONG |
|
Summary: Holding long ABBV as price pulls back to potential support near $224 in broader uptrend, with no volume capitulation or imminent catalysts signaling reversal, supported by strong pharma pipeline and positive momentum from recent highs....
|
|
| 2025-11-28 | HOLD LONG |
|
Summary: Holding long ABBV position as price remains above key $226 support after recent pullback in ongoing uptrend, supported by strong pharma fundamentals and no imminent negative catalysts....
|
|
| 2025-11-26 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend continues with price near rising EMA/SMA, positive MACD momentum, recent bounce from $226 support, and strong pharma fundamentals including positive clinical updates on key drugs like Skyrizi and Rinvoq....
|
|
| 2025-11-25 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend persists with price above rising EMA/SMA, positive MACD momentum, and recent bounce from $228 support amid pharma sector tailwinds from positive clinical trial updates....
|
|
| 2025-11-24 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend continues with price above rising EMA/SMA, positive MACD, and recent pharma sector strength from positive drug trial news, despite short-term pullback from $237 high....
|
|
| 2025-11-21 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend persists with price above rising EMA/SMA, positive MACD, recent breakout above $235 resistance on high volume, supported by strong pharma sector momentum and no near-term catalysts....
|
|
| 2025-11-20 | BUY |
|
Summary: Entering long ABBV in confirmed uptrend with price above rising EMA/SMA, positive MACD crossover signaling momentum, recent bounce from $212 support amid pharma sector strength and no imminent catalysts, targeting multi-week hold towards $235 resistance....
|
|
| 2025-11-19 | CASH |
|
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly bound and recent price crossings, while price nears resistance at $234.68 without a clear dip in the uptrend for a high-confidence long entry....
|
|
| 2025-11-17 | CASH |
|
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound and recently crossed, preventing new long entries despite positive momentum and no imminent catalysts, while ABBV's pharma nature precludes shorting. Both averages are gradually rising, but the tight coiling and cross suggest potential for whipsaw rather than a confirmed uptrend for safe entry. No volume capitulation in the past two months to justify buying a dip in any downtrend, and we're not in a downtrend anyway....
|
|
| 2025-11-14 | CASH |
|
Summary: Price is near resistance at $234.68 in an unclear trend with EMA slightly below SMA, suggesting waiting for a pullback to support around $215 for a stronger long setup amid positive pharma momentum....
|
|
| 2025-11-13 | CASH |
|
Summary: Trend remains unclear with EMA slightly below SMA despite price above both and both rising, avoiding new long entry after recent recovery from post-earnings dip, while ABBV's pharma stability and lack of short-term downside risks keep cash position prudent without high-confidence setup....
|
|
| 2025-11-12 | CASH |
|
Summary: Staying in cash as the trend is unclear with EMA slightly below SMA, price near resistance at $234.68 without a clear dip in an uptrend, and no high-confidence setup for entry following the recent post-earnings recovery. RSI at 62.44 is neutral, MACD is negative but improving (-0.46 line, -0.87 signal), and the stock is testing resistance at $234.68 with support at $215.84. No recent volume capitulation, and the price is at the top of the range, so avoiding buying here to prevent a poor entry....
|
|
| 2025-11-11 | CASH |
|
Summary: Staying in cash due to unclear trend with EMA below SMA despite price above both, recent volatility from earnings miss, and no high-confidence long setup for multi-week hold amid pharmaceutical sector stability....
|
|
| 2025-11-10 | CASH |
|
Summary: Staying in cash as the trend is unclear with EMA below SMA, price below both, and recent volatility post-earnings drop without a confirmed uptrend for a new long entry....
|
|
| 2025-11-07 | CASH |
|
Summary: Unclear trend with recent EMA/SMA cross, price below both after earnings miss drop, no volume capitulation for dip buy in potential downtrend, staying opportunistic for high-confidence long setup amid pharma stability....
|
|
| 2025-11-06 | CASH |
|
Summary: Staying in cash as the trend is unclear with price below both EMA and SMA after a post-earnings drop, no volume capitulation, and no high-confidence setup for entry despite some recovery....
|
|
| 2025-11-05 | CASH |
|
Summary: Trend is unclear with price below both EMA and SMA after recent post-earnings drop, no volume capitulation flagged, and earnings reportedly today introducing high volatility risk, so staying in cash for a better entry opportunity....
|
|
| 2025-11-04 | CASH |
|
Summary: Staying in cash due to unclear trend with price below both EMA and SMA, recent earnings miss causing volatility, and next earnings on 11/5/2025 precluding new entry. Technicals indicate EMA at 224.21 above SMA at 222.58, but price remains below both and not in a confirmed uptrend for entry, with MACD negative at -1.374 and RSI at 39.67 suggesting potential for further downside without capitulation volume. Support nearby at $215.84 (strength 2) was tested recently, but no strong bounce yet, and the stock is churning sideways below moving averages, increasing whipsaw risk....
|
|
| 2025-11-03 | CASH |
|
Summary: Trend is unclear with price below EMA and SMA, no volume capitulation, and earnings on 11/5/2025 approaching, so stay in cash to avoid risk....
|
|
| 2025-10-31 | CASH |
|
Summary: Post-earnings drop below MAs renders trend unclear without volume capitulation, so staying in cash awaiting clearer uptrend confirmation for long entry in this pharma stock....
|
|
| 2025-10-30 | CASH |
|
Summary: Staying in cash due to confirmed uptrend but imminent earnings on 10/31/2025, avoiding entry right before potential volatility despite no recent volume capitulation and positive momentum from recent support bounces. No flagged volume capitulation in the last two months, so no contrarian buy signal against the trend. Support levels at $215.84 (recently tested) and rising trendlines around $212-206 provide a floor, with the stock bouncing off these in mid-October pullbacks, suggesting potential for continuation post-earnings if results are strong....
|
|
| 2025-10-29 | CASH |
|
Summary: Staying in cash due to unclear uptrend with price slightly below EMA despite both moving upward, recent pullback from highs without volume capitulation, and upcoming earnings on 10/31/2025 within 3 days, where historical surprises don't meet criteria to hold long through the event....
|
|
| 2025-10-28 | CASH |
|
Summary: Staying in cash due to approaching earnings on 10/31/2025, recent pullback without volume capitulation, and unclear near-term direction amid overbought signals from prior rally. However, the stock experienced a sharp run-up in early October, peaking near $244 on 10/1 before pulling back about 7% to current levels, forming a potential hammer candlestick on 10/28, which could signal a bottom, but it's unconfirmed without follow-through volume or price action. Support is evident around $215-$220 from recent bounces and rising trendlines, while resistance looms at $232-$235 from prior highs. Technical indicators like RSI at 50.7 (neutral), MACD positive but converging (1.7655 line vs 2.8505 signal, suggesting waning momentum), and Stochastic %K at 25.4 (oversold) point to possible stabilization, but no volume capitulation flagged in the past two months means we can't justify buying this dip in what might still be a corrective phase....
|
|
| 2025-10-27 | CASH |
|
Summary: Staying in cash due to upcoming earnings on 10/31/2025, confirmed uptrend but avoiding entry right before catalyst without meeting hold-through criteria, recent pullback from highs around 244 to 227 with support at 215.84 holding....
|
|
| 2025-10-24 | CASH |
|
Summary: Staying in cash due to upcoming earnings on 10/31/2025 without meeting hold-through criteria, despite uptrend and hammer candlestick suggesting a potential dip-buy opportunity, as minimum hold would require carrying through the event....
|
|
| 2025-10-22 | CASH |
|
Summary: Staying in cash due to recent exit on 10/21 amid pre-earnings volatility, with next earnings on 10/31/2025 too close for a new multi-week long entry in this uptrend without violating hold requirements or risking event uncertainty. ...
|
|
| 2025-10-21 | SOLD |
|
Summary: Exiting long ABBV to secure substantial gains from $210.42 entry amid recent volatility and approaching October 31 earnings, despite strong uptrend and positive momentum....
|
|
| 2025-10-20 | HOLD LONG |
|
Summary: Holding long ABBV as uptrend persists with price above EMA and SMA, recovering from support near $227 with positive MACD momentum and supportive pharma news on pipeline advancements without reversal signals....
|
|
| 2025-10-17 | HOLD LONG |
|
Summary: Holding long ABBV in confirmed uptrend with price above EMA and SMA, recent breakout recovery from support around $226, positive MACD momentum, and supportive pharma sector news on drug pipeline without imminent reversal risks. Price has bounced from a rising trendline support near $226.74, last tested recently, aligning with historical patterns where similar pullbacks in uptrends led to continuations, as seen in July-August rallies post-earnings....
|
|
| 2025-10-16 | HOLD LONG |
|
Summary: Holding long ABBV as it remains in a confirmed uptrend with price above EMA and SMA, recent pullback finding support at rising trendline around $226, positive momentum indicators, and no immediate reversal signals despite upcoming earnings risk....
|
|
| 2025-10-15 | HOLD LONG |
|
Summary: Holding long ABBV in confirmed uptrend with price above EMA and SMA, recent bounce from rising support at $225.32 after pullback from $244 high, supported by positive momentum and no imminent catalysts or reversal signals....
|
|
| 2025-10-13 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend continues with price above EMA and SMA, recovering from recent pullback without reversal signals, supported by positive momentum and no immediate catalysts, aiming for resistance near 233-234 before earnings....
|
|
| 2025-10-10 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend persists with price above EMA and SMA, recent pullback from highs offers no reversal signals, supported by positive momentum and no imminent catalysts, targeting hold towards resistance near 234 before upcoming earnings....
|
|
| 2025-10-09 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend remains strong with price above EMA and SMA, recent gap-up on positive news supports momentum, no reversal signals, and earnings not imminent....
|
|
| 2025-10-07 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend persists with price above EMA and SMA after a pullback from recent highs, supported by strong volume on the breakout and positive pharma sector momentum, with no clear reversal signals or imminent events....
|
|
| 2025-10-06 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend remains intact with price above EMA and SMA, recent pullback from highs appears as a healthy dip supported by strong volume on the prior breakout and positive pipeline momentum, with no reversal signals or imminent catalysts warranting exit after 19-bar hold from $210.42 entry....
|
|
| 2025-10-03 | HOLD LONG |
|
Summary: Holding long ABBV as the clear uptrend persists with price well above EMA and SMA, recent breakout to new highs on strong volume and positive momentum, supported by bullish fundamentals like robust pipeline updates and no imminent reversal signals....
|
|
| 2025-10-02 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend remains intact with price above EMA and SMA, strong momentum from recent highs on positive news, and no clear reversal signals despite today's pullback. Technical indicators support continuation: MACD is positive at 6.8754 with the line above signal, RSI at 70.25 indicates strength without extreme overbought levels, and Stochastic shows bullish momentum. Volume on the recent surge to 244.81 on 10/1 was high at over 12 million shares, suggesting strong buying interest, though today's pullback to 236.93 on lower volume appears as a healthy consolidation rather than a reversal....
|
|
| 2025-10-01 | HOLD LONG |
|
Summary: Holding long ABBV as the clear uptrend persists with price surging above EMA and SMA to new highs on strong volume, positive MACD momentum, and no reversal signals or imminent catalysts. Technical indicators support continuation: MACD is positive at 6.38 with the signal line at 5.01, RSI at 83.68 indicates overbought but not extreme given the momentum, and Stochastic is high but aligned with bullish trends. Bollinger Bands are expanding upward, with price near the upper band, suggesting strong buying pressure. Support from rising trendlines around $220 and historical levels at $205 provide downside protection, and there's no volume capitulation or bearish divergence to signal a top....
|
|
| 2025-09-30 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend remains intact with price well above EMA and SMA, strong bullish momentum to new highs, positive MACD, and no imminent catalysts or reversal signals. Technical indicators support continuation: MACD is positive at 4.9744 above its signal line at 4.6755, RSI at 76.86 is elevated but not extremely overbought in the context of this stock's historical rallies, and Stochastic is high at 92.69, reflecting sustained buying pressure. Volume on the upside break was solid at 4.7M shares, and there's no flagged volume capitulation to suggest exhaustion. Key supports include a rising trendline around $219.17 recently tested, with additional levels at $205.1 showing strength from prior bounces—avoiding entries near bottoms but here we're already positioned well above....
|
|
| 2025-09-29 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend persists with price above EMA and SMA, positive MACD, strong momentum to recent highs near 223 resistance, no reversal signals, and no imminent catalysts within 3 days....
|
|
| 2025-09-26 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend continues with price above EMA and SMA, positive MACD, strong momentum from recent highs, and no imminent catalysts or reversal signals....
|
|
| 2025-09-25 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend persists with price above EMA and SMA, positive MACD and momentum, no reversal signals, and supportive sector trends without near-term catalysts. Recent bars display higher highs and lows, supported by rising trendlines like the one from $202.77 with positive slope, last tested around late July. Volume has been steady without capitulation, and indicators like MACD at 4.52 (above signal) and RSI at 61.57 indicate sustained bullish momentum without overbought conditions....
|
|
| 2025-09-24 | HOLD LONG |
|
Summary: Maintaining long ABBV position as the uptrend remains intact with price above EMA and SMA, positive MACD, RSI not overbought, no reversal signals near recent highs, and supportive pharma sector trends without imminent catalysts....
|
|
| 2025-09-23 | HOLD LONG |
|
Summary: Maintaining long ABBV position in strong uptrend with price above EMA/SMA, positive MACD and RSI, recent highs at 225 without reversal, supported by bullish pharma sector momentum and no near-term catalysts, targeting 230 resistance....
|
|
| 2025-09-22 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend continues with price above EMA/SMA, bullish MACD and momentum, recent highs near 225 without reversal, targeting 230 resistance amid positive pharma news....
|
|
| 2025-09-19 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend persists with price above EMA/SMA, bullish MACD, recent breakout to new highs near 223, no reversal signals, and positive momentum from pharma sector strength, targeting 225-230 resistance....
|
|
| 2025-09-18 | HOLD LONG |
|
Summary: Maintaining long ABBV position in continued uptrend with price above EMA/SMA, positive MACD, recent highs near 221, no reversal signals, and supportive pharma news, targeting 225-230 resistance....
|
|
| 2025-09-17 | HOLD LONG |
|
Summary: Maintaining long ABBV position in strong uptrend with price above EMA/SMA, positive MACD, recent breakout to new highs above 215 resistance, and no reversal signals or imminent catalysts, targeting 225-230 zone....
|
|
| 2025-09-16 | HOLD LONG |
|
Summary: Maintaining long ABBV position in confirmed uptrend with price above EMA/SMA, positive MACD, no reversal signals, recent breakout above 210-215 resistance, and targeting 225-230 zone amid stable pharma sector and no imminent catalysts....
|
|
| 2025-09-15 | HOLD LONG |
|
Summary: Maintaining long ABBV position in confirmed uptrend with price above EMA/SMA, positive MACD momentum, no reversal signals, recent breakout to 220 highs, and targeting 225-230 resistance zone amid stable pharma fundamentals. Technical indicators support continuation: MACD at 4.5379 remains bullish above its signal line (4.3323), RSI at 67.2 indicates room for upside without overbought conditions, and Stochastic %K/%D (79.68/80.84) shows sustained momentum. Recent bars reflect a high-volume breakout above 212 resistance on 9/11, pushing to 220+ highs, mirroring past patterns like the July post-earnings rally from 189 to 198, where we captured gains without early exits....
|
|
| 2025-09-12 | HOLD LONG |
|
Summary: Maintaining long ABBV position amid confirmed uptrend with price above EMA/SMA, recent high-volume breakout above 212 resistance to new highs near 220, positive MACD and momentum, no reversal signals, and targeting 225-230 zone....
|
|
| 2025-09-11 | HOLD LONG |
|
Summary: Maintaining long ABBV position as the strong uptrend persists with price well above EMA/SMA, recent breakout to new highs on high volume, positive MACD momentum, and no reversal signals or imminent catalysts, targeting further upside toward 225-230 resistance....
|
|
| 2025-09-10 | HOLD LONG |
|
Summary: Maintaining long position in ABBV as the uptrend remains intact with price above EMA and SMA, recent close near but not exceeding 212.88 resistance, and no immediate catalysts or reversal signals after just one bar hold, targeting further upside toward 215. MACD is positive at 3.7905 with signal at 4.1955, though slightly diverging, but momentum indicators like RSI at 65.56 suggest room before overbought territory. Volume is moderate at 3.2M, not indicating exhaustion....
|
|
| 2025-09-09 | BUY |
|
Summary: Entering long in confirmed uptrend with price above EMA and SMA, positive MACD crossover, and bullish momentum from recent highs, supported by strong pharma fundamentals and no imminent catalysts, targeting multi-week hold towards 215 resistance. Technical indicators are supportive: RSI at 62.3 indicates room for upside without being overbought, MACD at 3.89 with signal at 4.29 showing positive momentum, and the price is within Bollinger Bands, not at the upper extreme (upper at 215.27). Support levels at 182.37 and rising trendlines around 195-198 provide a safety net, while resistance at 212.88 suggests potential for a move higher....
|
|
| 2025-09-08 | CASH |
|
Summary: Staying in cash as the uptrend persists but current price at 209.04 isn't a meaningful dip from recent highs near 213 or our 8/29 exit at 210.4, with no new catalysts justifying quick re-entry and potential resistance at 212.88 ahead....
|
|
| 2025-09-05 | CASH |
|
Summary: Staying in cash as the uptrend persists but price is near resistance at $212.88 without a clear dip for entry, and we recently exited at $210.4 with no significant new bullish catalysts to justify re-entry so soon at a higher price....
|
|
| 2025-09-04 | CASH |
|
Summary: Staying in cash as ABBV is in a clear uptrend but trading near resistance at $212.88 without a dip for entry, following recent exit on 8/29 at $210.4 to avoid chasing highs....
|
|
| 2025-09-03 | CASH |
|
Summary: Staying in cash as ABBV is in a confirmed uptrend but trading near resistance at $212.88 with no clear breakout, avoiding entry at the top of the range after recent exit on 8/29/2025 at $210.4....
|
|
| 2025-09-02 | CASH |
|
Summary: Staying in cash as ABBV is in an uptrend but trading near resistance at $212 with no clear dip for entry, following recent exit on 8/29/2025 at $210.4 amid overbought conditions and lack of new bullish catalysts....
|
|
| 2025-08-29 | SOLD |
|
Summary: Exiting long ABBV near $212 resistance after 13-bar hold from $198.64 entry, capturing gains in confirmed uptrend without reversal signals, supported by positive momentum and no imminent catalysts....
|
|
| 2025-08-28 | HOLD LONG |
|
Summary: Holding long in ABBV as the uptrend remains confirmed with price above both EMA and SMA, recent price action showing continued momentum toward $212 resistance without reversal signals, supported by positive sector trends and no imminent catalysts....
|
|
| 2025-08-27 | HOLD LONG |
|
Summary: Holding long in ABBV's confirmed uptrend with price above EMA and SMA, recent highs showing momentum, no reversal signals, and potential to test $212 resistance amid positive pharma sector tailwinds. Momentum indicators like MACD at 4.61 (positive and rising) and RSI at 66.43 (bullish but not overbought) support continuation, while Slow STO K/D at 86.16/91.46 indicates sustained buying pressure. Price is climbing toward the $212.88 resistance level noted in the chart, with historical patterns showing ABBV often extends rallies post-earnings or positive news, as seen in the July bounce from 186 to 198 before our entry....
|
|
| 2025-08-26 | HOLD LONG |
|
Summary: Holding long as ABBV remains in a confirmed uptrend with price above EMA and SMA, positive momentum from recent highs, no volume capitulation or imminent reversals, and approaching $212 resistance for potential multi-week extension....
|
|
| 2025-08-25 | HOLD LONG |
|
Summary: Holding long in confirmed uptrend with price above EMA/SMA, momentum building toward $212 resistance after recent consolidation, no imminent catalysts or reversals, and position requires extended hold....
|
|
| 2025-08-22 | HOLD LONG |
|
Summary: Holding long as uptrend persists with price above EMA/SMA, momentum toward $212 resistance intact, and position only 8 bars old requiring extended hold without reversal....
|
|
| 2025-08-21 | HOLD LONG |
|
Summary: Holding the long position as the stock remains in a confirmed uptrend with price above EMA and SMA, strong momentum continuing toward $212 resistance without reversal signals, and entry only 7 bars ago necessitating longer hold per strategy....
|
|
| 2025-08-20 | HOLD LONG |
|
Summary: Continuing to hold the long position in a confirmed uptrend with price above EMA and SMA, strong upward momentum pushing toward resistance at $212, no reversal signals yet, and entry only 6 bars ago requiring longer hold. Momentum indicators like MACD (4.5795 line above 3.4743 signal) and RSI (73.55, overbought but not extreme) support continued strength, as price has broken through prior highs and is approaching the noted resistance at $212.88. Visual indicators include a rising support trendline at $206.44 with recent bounces, aligning with the ongoing rally....
|
|
| 2025-08-19 | HOLD LONG |
|
Summary: Holding long in confirmed uptrend with price above EMA and SMA, strong momentum from recent rally, no reversal signals, and aiming for resistance near $212 while monitoring for pullbacks....
|
|
| 2025-08-18 | HOLD LONG |
|
Summary: Continuing to hold long position in strong uptrend with price above EMA and SMA, recent momentum pushing toward $212 resistance after positive earnings momentum, no reversal signals or immediate catalysts....
|
|
| 2025-08-15 | HOLD LONG |
|
Summary: Holding long in confirmed uptrend with price above EMA/SMA, building momentum toward $218 resistance after positive Q2 earnings beat and raised guidance, no immediate catalysts or reversal signals....
|
|
| 2025-08-14 | HOLD LONG |
|
Summary: Holding long in strong uptrend with price above EMA/SMA, continuing post-earnings momentum from July 31 beat, targeting $218 resistance amid positive pharma stability and no near-term catalysts....
|
|
| 2025-08-13 | HOLD LONG |
|
Summary: Holding long position in confirmed uptrend with price above EMA and SMA, building on post-earnings momentum from July 31 beat and raised guidance, targeting resistance near $218 with no immediate catalysts....
|
|
| 2025-08-12 | BUY |
|
Summary: Entering long in confirmed uptrend with price above EMA and SMA, following recent post-earnings strength and positive momentum near resistance, aiming for multi-week hold....
|
|
| 2025-08-11 | CASH |
|
Summary: Staying in cash as ABBV is near resistance at $198.98 in an uptrend but not on a clear dip, avoiding entry at the top of the range for a high-confidence multi-week long setup....
|
|
| 2025-08-08 | CASH |
|
Summary: Staying in cash as ABBV is in a clear uptrend post strong Q2 earnings beat and raised 2025 guidance, but current price near $198.98 resistance after recent rally suggests waiting for a dip to support like the rising trendline at ~$189 for a high-confidence long entry with favorable risk/reward....
|
|
| 2025-08-07 | SOLD |
|
Summary: Exiting long position near $198.98 resistance after post-earnings rally from $189.02 entry, locking in gains in confirmed uptrend with price above EMA/SMA, supported by strong Q2 results and raised 2025 guidance, no immediate reversal but opportunistic to take profits before potential pullback....
|
|
| 2025-08-06 | HOLD LONG |
|
Summary: Holding long position as uptrend continues with price above EMA/SMA, supported by strong Q2 earnings beat and raised guidance, no reversal signals despite approaching $198.98 resistance....
|
|
| 2025-08-05 | HOLD LONG |
|
Summary: Holding long in ongoing uptrend with price above EMA/SMA, positive momentum from Q2 earnings beat and raised guidance, nearing $198-200 resistance but no immediate catalysts or trend reversal signals....
|
|
| 2025-08-04 | HOLD LONG |
|
Summary: Continuing to hold long position post-Q2 earnings beat with raised guidance, as price remains in clear uptrend above EMA/SMA, recent highs at $196.42 signaling momentum toward $198-200 resistance over next weeks without immediate catalysts....
|
|
| 2025-08-01 | HOLD LONG |
|
Summary: Holding long position entered post strong Q2 earnings beat and raised guidance, with price in clear uptrend above EMA/SMA, recent breakout above $190 resistance on high volume signaling potential push to $198.98 level over next weeks....
|
|
| 2025-07-31 | BUY |
|
Summary: Entering long after positive Q2 earnings beat with strong Skyrizi/Rinvoq revenue and raised guidance, in clear uptrend with price above EMA/SMA, pulling back from intraday high near resistance for favorable entry....
|
|
| 2025-07-30 | CASH |
|
Summary: Staying in cash due to unclear trend with tightly bound EMA/SMA, frequent price crossings without capitulation, and impending earnings on July 31 that could introduce volatility despite positive analyst expectations....
|
|
| 2025-07-29 | CASH |
|
Summary: Staying in cash to avoid potential volatility from AbbVie's Q2 2025 earnings release on July 31, despite the current uptrend with EMA above SMA and price above both, positive analyst sentiment including buy ratings and a $250 target from recent reports, and strong fundamentals like immunology drug growth....
|
|
| 2025-07-28 | CASH |
|
Summary: Staying in cash to avoid potential volatility from the upcoming Q2 earnings on July 31, despite positive fundamental news on immunology drugs and an unclear but leaning uptrend with price near support....
|
|
| 2025-07-25 | SOLD |
|
Summary: Exiting long position ahead of July 31 earnings to avoid potential volatility from possible EPS miss, despite current uptrend and positive news on immunology drugs....
|
|
| 2025-07-24 | HOLD LONG |
|
Summary: Maintaining long position as uptrend persists with EMA above SMA, price above both, positive MACD crossover, and supportive fundamentals including strong Q1 earnings and upcoming Q2 results expected to show growth, despite earnings proximity....
|
|
| 2025-07-23 | HOLD LONG |
|
Summary: Holding long position in ABBV uptrend with price above EMA/SMA, positive fundamentals including Q1 earnings surge and analyst buy ratings targeting $250, despite upcoming Q2 earnings on July 31, 2025, as expectations remain strong for revenue and EPS growth....
|
|
| 2025-07-22 | HOLD LONG |
|
Summary: Holding long position as positive Q1 results, raised guidance, analyst buy ratings, and recent patent win support favorable Q2 earnings outcome on July 25 despite unclear trend, with price bouncing from support near entry for multi-week upside potential....
|
|
| 2025-07-18 | HOLD LONG |
|
Summary: Continuing the long position in ABBV as it holds above the rising support trendline with positive MACD crossover and neutral RSI, maintaining the multi-week hold setup from $186.39 amid stable pharma sector outlook....
|
|
| 2025-07-17 | HOLD LONG |
|
Summary: Holding long position in ABBV as it continues upward momentum from recent support bounce with positive MACD crossover and neutral RSI, supported by pharma sector stability and no major bearish catalysts....
|
|
| 2025-07-16 | HOLD LONG |
|
Summary: Holding the existing long position as ABBV continues upward momentum from the rising support trendline at $185 with positive MACD crossover, neutral RSI, and bullish catalysts like strong drug pipeline updates, for a multi-week hold targeting resistance near $194....
|
|
| 2025-07-15 | BUY |
|
Summary: Bounced off rising support trendline at $185.01 with positive MACD and neutral RSI, offering high-confidence long setup near support for multi-week hold amid pharma stability.
|
|